Xilio Therapeutics opened lower at $8.38, compared with its previous close of $8.47. In the last trading session, the stock traded between $7.96 and $8.25. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Xilio Therapeutics is now worth
$ 2.48
Resulting in a loss of
$ 97.52 (97.52%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
$-0.23 (-2.72%)
Day High
$8.25
Day Low
$7.96
Day Open
$8.38
Prev Close
$8.47
Volume
8,381
1W Return
-5.87%
1M Return
-9.45%
3M Return
-9.54%
6M Return
6.60%
1Y Return
-25.91%
Market Cap ($ Mn)
58
PE Ratio
-
PB Ratio
0.82
PEG Ratio
-
ROE
-280.09%
ROCE
-49.19%
EPS (TTM)
$-0.90
1 Week
-5.87%
1 Month
-9.45%
3 Months
-9.54%
6 Months
6.60%
9 Months
10.01%
Xilio Therapeutics Q3 Results: Loss narrows to $0.30 per share
Xilio Therapeutics posted a Q3 loss of $0.30 per share, beating the $0.82 estimate. Revenue of $9.984 million exceeded forecasts by 106.28%. Topline sales declined 47.63% from $19.066 million in the prior year. Net loss narrowed by 81.01% compared to the same quarter last year.
2 days agoRaymond James initiates Xilio Therapeutics with Outperform rating
Raymond James initiated coverage on Xilio Therapeutics. Analyst Sean McCutcheon assigned an Outperform rating. Price target established at $16.
22 days agoXilio Therapeutics grants stock options to new CMO and staff
Xilio Therapeutics granted options for 205,895 shares to three new hires. Yariv Houvras, newly appointed Chief Medical Officer, received 105,000 options. Exercise price set at $8.91 per share, equal to October 1, 2026 closing price. Grants made under Nasdaq Listing Rule 5635(c)(4) as employment inducement.
1mo agoXilio Therapeutics appoints Yariv J. Houvras as chief medical officer
Xilio Therapeutics appointed Dr. Yariv J. Houvras as chief medical officer on September 28, 2026. Houvras previously led clinical development at Tubulis and oversaw linvoseltamab approval at Regeneron. Appointment supports advancement of XTX501 and next-generation masked T cell engagers. Houvras brings 20+ years of experience in immuno-oncology and translational medicine.
1mo agoXilio Therapeutics grants 19,865 stock options to new hires
Xilio Therapeutics granted 19,865 non-qualified stock options to two new employees. Exercise price set at $8.88 per share, matching the Sept 1 closing price. Grants comply with Nasdaq Listing Rule 5635(c)(4) for new hire inducements. Vesting schedule includes 25% cliff after one year and monthly installments thereafter.
2mo agoXilio Therapeutics Q2 Results: Sales up 131% YoY to $18.7M
Xilio Therapeutics Q2 results show EPS of $(0.33) and sales of $18.692M, beating estimates by 44% and 47% respectively. Revenue surged 131% YoY while losses narrowed 85%, signaling improved operational leverage despite continued net losses.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Xilio Therapeutics is now worth
$ 2.48
Resulting in a loss of
$ 97.52 (97.52%)
Note: Past profits do not guarantee future returns.
